Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis

被引：0
|
作者：
Mease, Philip [1 ]
Smolen, Josef [2 ]
Kavanaugh, Arthur [3 ]
Nash, Peter [4 ]
Gallo, Gaia [5 ]
Liu-Leage, Soyi [5 ]
Sapin, Christophe [5 ]
Genovese, Mark [6 ]
Bessette, Louis [7 ]
机构：
[1] Univ Washington, Seattle, WA USA
[2] Med Univ Vienna, Vienna, Austria
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Univ Queensland, Brisbane, Qld, Australia
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Stanford Univ, Palo Alto, CA 94304 USA
[7] Laval Univ, Quebec City, PQ, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2021年 / 48卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
125
引用
收藏
页码：1167 / 1167
页数：1
相关论文
共 50 条
  • [1] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Smolen, J. S.
    Kavanaugh, A.
    Nash, P.
    Gallo, G.
    Leage, S. Liu
    Sapin, C.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698
  • [2] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [3] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda M.
    Leage, Soyi Liu
    Pillai, Sreekumar G.
    Mease, Philip
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 17 - 17
  • [4] A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY
    Chaudhury, Sukanya
    Gellett, Amanda M.
    Hojnik, Maja
    Leage, Soyi Liu
    Li, Lingnan
    Mease, Philip
    Nash, Peter
    Pillai, Sreekumar G.
    Schulze-Koops, Hendrik
    Smolen, Josef
    Tahir, Hasan
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 125 - 125
  • [5] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor study
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip
    Bessette, Louis
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1042 - 1042
  • [6] Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes
    Edwards, C. J.
    Bradley, A.
    Nassab, M. H.
    Moller, B.
    Machold, K. P.
    Sapin, C.
    Ranza, R.
    Liu-Leage, S.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
  • [7] IXEKIZUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES
    Chaudhury, Koyel
    Bradley, Andrew
    Nassab, Mani Haschemi
    Moeller, Burkhard
    Machold, Klaus P.
    Sapin, Christophe
    Ranza, Roberto
    Leage, Soyi Liu
    Nash, Peter
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 33 - 34
  • [8] A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
    Mease, Philip J.
    Smolen, Josef S.
    Behrens, Frank
    Nash, Peter
    Leage, Soyi Liu
    Li, Lingnan
    Tahir, Hasan
    Gooderham, Melinda
    Krishnan, Eswar
    Liu-Seifert, Hong
    Emery, Paul
    Pillai, Sreekumar G.
    Helliwell, Philip S.
    Naftal, Leonardo
    Hidalgo, Rodolfo Ariel Pardo
    Kerzberg, Eduardo Mario
    Savio, Veronica Gabriela
    Lazaro, Alicia
    Velasco, Benito Jorge
    Verzero, Norma Beatriz
    Asnal, Cecilia Adma
    Mysler, Eduardo Fabian
    Berman, Alberto
    Ariel, Federico Javier
    Rischmueller, Maureen
    Zochling, Jane Margaret
    Bird, Paul A.
    Hall, Stephen
    Ostor, Andrew
    Romas, Evange
    Stummvoll, Georg
    Machold, Klaus
    Spellitz, Peter
    Hanusch, Ursula
    Vanden Berghe, Marc
    Leon, Marc
    Vanhoof, Johan Louis Magda
    Van den Bosch, Filip Eduard Jeanne
    De Vlam, Kurt Leo Francois
    Morin, Frederic
    Bessette, Louis
    Haaland, Derek A.
    Schlemmer, Annette Margrethe
    Kristensen, Lars Erik
    Jarvinen, Pentti
    Peltomaa, Ritva Liisa
    Pirila, Laura
    Vuotila, Jorma
    Lespessailles, Eric
    Goupille, Philippe
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (01) : 123 - 131
  • [9] A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
    Smolen, Josef
    Nash, Peter
    Tahir, Hasan
    Schulze-Koops, Hendrik
    Li, Lingnan
    Hojnik, Maja
    Gellett, Amanda
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [10] 52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Okada, Masan
    Kishimoto, Mitsumasa
    Shuler, Catherine
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 925
12345